HK1207296A1 - 基於基因型或表型的藥物製劑 - Google Patents

基於基因型或表型的藥物製劑

Info

Publication number
HK1207296A1
HK1207296A1 HK15107896.3A HK15107896A HK1207296A1 HK 1207296 A1 HK1207296 A1 HK 1207296A1 HK 15107896 A HK15107896 A HK 15107896A HK 1207296 A1 HK1207296 A1 HK 1207296A1
Authority
HK
Hong Kong
Prior art keywords
genotype
phenotype
drug formulation
based drug
formulation
Prior art date
Application number
HK15107896.3A
Other languages
English (en)
Inventor
Stefan Willmann
Thomas Eiing
Kristin Dickschen
Original Assignee
Bayer Technology Services Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services Gmbh filed Critical Bayer Technology Services Gmbh
Publication of HK1207296A1 publication Critical patent/HK1207296A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
HK15107896.3A 2012-06-01 2015-08-17 基於基因型或表型的藥物製劑 HK1207296A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
PCT/EP2013/060824 WO2013178565A1 (de) 2012-06-01 2013-05-27 Genotyp- bzw. phänotyp-basierte arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
HK1207296A1 true HK1207296A1 (zh) 2016-01-29

Family

ID=48520964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107896.3A HK1207296A1 (zh) 2012-06-01 2015-08-17 基於基因型或表型的藥物製劑

Country Status (23)

Country Link
US (3) US10285958B2 (zh)
EP (2) EP2668945A1 (zh)
JP (2) JP6096289B2 (zh)
KR (1) KR102129043B1 (zh)
CN (2) CN104507464A (zh)
AR (2) AR091234A1 (zh)
AU (1) AU2013269793B2 (zh)
BR (1) BR112014030059B1 (zh)
CA (1) CA2875189C (zh)
DK (1) DK2854789T3 (zh)
ES (1) ES2744306T3 (zh)
HK (1) HK1207296A1 (zh)
HU (1) HUE045699T2 (zh)
IL (1) IL235988B (zh)
MX (1) MX370304B (zh)
NZ (1) NZ702849A (zh)
PL (1) PL2854789T3 (zh)
PT (1) PT2854789T (zh)
RU (1) RU2683260C2 (zh)
SA (1) SA113340607B1 (zh)
SG (2) SG11201407791VA (zh)
TW (1) TWI644666B (zh)
WO (1) WO2013178565A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
WO2005092314A1 (en) 2004-03-18 2005-10-06 Istituto Nazionale Per Lo Studio E La Cura Del Tum 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
US7805282B2 (en) 2004-03-30 2010-09-28 New York University Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
RU2007143087A (ru) 2005-06-02 2009-07-20 Биовэйл Лэборэториз Интернэшнл С.Р.Л. (Bb) Композиция с модифицированным высвобождением минимум одной формы венлафаксина
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
EP1938231A1 (en) 2005-09-19 2008-07-02 BG Medicine, Inc. Correlation analysis of biological systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
JP2010510327A (ja) 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ,インコーポレーテッド エンドキシフェンの方法および組成物
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CA2716456A1 (en) 2008-02-26 2009-09-03 Purdue Research Foundation Method for patient genotyping
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
US20110136913A1 (en) * 2008-08-19 2011-06-09 Goetz Matthew P Assessing and treating breast cancer patients
WO2010036732A1 (en) 2008-09-25 2010-04-01 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
US20120088247A1 (en) 2009-02-23 2012-04-12 Indian University Research & Technology Corporatio Materials and methods for treating patients with taxoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
NZ606903A (en) * 2010-08-26 2015-05-29 Ipca Lab Ltd Methods for the treatment or prophylaxis of thrombosis or embolism
EP2675813A4 (en) * 2011-06-27 2014-04-30 Ipca Lab Ltd ANTI THROMBOSIS CONNECTIONS
EP2834366A4 (en) 2012-04-02 2016-04-27 Berg Llc QUESTION-BASED ASSAYS AND USES THEREOF
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
TW201400109A (zh) 2014-01-01
JP2017048234A (ja) 2017-03-09
SG11201407791VA (en) 2015-01-29
NZ702849A (en) 2016-09-30
BR112014030059A2 (pt) 2017-07-25
EP2668945A1 (de) 2013-12-04
WO2013178565A1 (de) 2013-12-05
EP2854789A1 (de) 2015-04-08
IL235988B (en) 2018-11-29
AU2013269793A1 (en) 2015-01-22
EP2854789B1 (de) 2019-06-26
JP2015519350A (ja) 2015-07-09
US20170326081A1 (en) 2017-11-16
US10285958B2 (en) 2019-05-14
KR102129043B1 (ko) 2020-07-01
US20150174082A1 (en) 2015-06-25
ES2744306T3 (es) 2020-02-24
HUE045699T2 (hu) 2020-01-28
PL2854789T3 (pl) 2019-12-31
CN110075097A (zh) 2019-08-02
SG10201610072UA (en) 2017-01-27
TWI644666B (zh) 2018-12-21
PT2854789T (pt) 2019-09-18
MX370304B (es) 2019-12-09
AR091234A1 (es) 2015-01-21
CA2875189C (en) 2020-09-22
KR20150022894A (ko) 2015-03-04
CN104507464A (zh) 2015-04-08
DK2854789T3 (da) 2019-09-16
SA113340607B1 (ar) 2018-05-09
AR118842A2 (es) 2021-11-03
IL235988A0 (en) 2015-01-29
RU2683260C2 (ru) 2019-03-27
RU2014154140A (ru) 2016-07-27
CA2875189A1 (en) 2013-12-05
AU2013269793B2 (en) 2018-03-01
MX2014014596A (es) 2015-03-03
JP6096289B2 (ja) 2017-03-15
US20170326080A1 (en) 2017-11-16
BR112014030059B1 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
HK1208372A1 (zh) 液體製劑
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1205146A1 (zh) 藥物製劑
HK1202445A1 (zh) 新製劑
ZA201306000B (en) Stable formulation
HK1205679A1 (zh) 尼古丁製劑
HK1205683A1 (zh) 穩定性提高的藥物製劑
LT2934544T (lt) Farmacinė kompozicija, apimanti ciklezonidą
EP2822599A4 (en) VACCINE
HK1207296A1 (zh) 基於基因型或表型的藥物製劑
HK1206269A1 (zh) 包含苯達莫司汀的藥物製劑
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
SG11201406097SA (en) Capsule formulation
HK1209339A1 (zh) 藥物配方
HK1204945A1 (zh) 含有氟吡汀的藥物製劑
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL244316A0 (en) A new composition of a drug
IL234771A0 (en) Nicotine formulation
GB201211247D0 (en) Improved formulation
ZA201400751B (en) Pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations